Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase–Producing P. aeruginosa Sequence Type 463, Associated With High Mortality Rates in China: A Retrospective Cohort Study

Hangbin Hu†, Yan Zhang†, Piaopiao Zhang†, Jie Wang2, Qing Yuan1, Weixiao Shi1, Sheng Zhang3, Haiting Feng3, Yunbo Chen1, Meihong Yu1, Hongchao Chen4, Yan Jiang5, Qing Yang4* and Tingting Qu1,3*

1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, 2 Respiratory Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 3 Infection Control Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 4 Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 5 Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

Objectives: Recently, KPC-producing P. aeruginosa has rapidly emerged and expanded in East China. Here we described the clinical impact and characteristics of bloodstream infections (BSIs) from the dominant KPC-producing CRPA belonging to Sequence Type (ST) 463.

Methods: Retrospective cohort study was performed with CRPA BSI cases from 2019 to 2020 in a hospital in East China. Clinical characteristics, risk factors, and all-course mortality were evaluated. All CRPA isolates had whole-genome sequencing, antimicrobial susceptibility testing, and serum resistance assay. Representative isolates were tested for virulence in a Galleria mellonella infection model.

Results: Among the 50 CRPA BSI cases, ST463 predominated (48.0%). In multivariate analysis, we found three independent risk factors for fatal outcome: KPC carriage (OR 4.8; CI95% 1.0-23.7; P = 0.05), Pitt bacteremia score (OR 1.3; CI95% 1.0-1.6; P = 0.02), and underlying hematological disease (OR 8.5; CI95% 1.6-46.4; P = 0.01). The baseline clinical variables were not statistically different across STs, however the 28-day mortality was significantly higher in ST463 cases than that in non-ST463 cases (66.7% vs 33.3%, P = 0.03). ExoU and exoS virulence genes coexisted in all ST463 isolates, and the carbapenem resistant gene blaKPC were produced in almost all ST463 isolates, significantly higher than in the non-ST463 group(95.8% vs 7.7%, P<0.001). ST463
CRPA isolates also showed higher resistance rates to antipseudomonal cephalosporins, monobactam, and fluoroquinolones. And ST463 CRPA was confirmed hypervirulence in the larvae model. The genome of one ST463 CRPA strain showed that the blaKPC-2 gene was the sole resistance gene located on a 41,104bp plasmid pZYPA01, carried on a 7-kb composite transposon-like element flanked by two IS26 elements (IS26–Tn3-trpA–ISKpn27–blaKPC-2–ISKpn6–IS26). Plasmid from various species presented core blaKPC-2 was flanked by mobile genetic element ISKpn27 and ISKpn6.

**Conclusions:** In the ST463 CRPA BSI cohort, the mortality rates were higher than those in the non-ST463 CRPA BSI. The ST463 CRPA clone coharboring the blaKPC and exoU/ exoS genes emerged and spread in East China, which might develop to a new threat in the clinic. Our results suggest that the surveillance of the new high-risk clone, ST463 CRPA, should be strengthened in China, even worldwide in the future.

**Keywords:** bloodstream infections, hypervirulence, carbapenem-resistant *Pseudomonas aeruginosa*, KPC, ST463

---

**INTRODUCTION**

*Pseudomonas aeruginosa* (PA) is a common and serious cause of nosocomial bloodstream infection; it is often severe when patients have compromised immunity. Despite improvements in medical care, the mortality of PA bacteremia remains considerably high (Thaden et al., 2017). Mortality in PA bloodstream infection is multifactorial, including the immune status of the host, the initial site of infection, the antibiotic treatment, and the microorganisms (Hu et al., 2021a). Moreover, the presence of carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) limits the treatment options and increases the risk of inadequate empirical therapy (Doi, 2019).

The common resistance mechanisms of *P. aeruginosa* to carbapenems are the loss of the outer membrane protein OprD and the overexpression of efflux pumps and/or the intrinsic chromosomally encoded AmpC β-lactamase (Li et al., 2012; Potron et al., 2015; Pang et al., 2019). Another mechanism for carbapenem resistance is the production of carbapenemases such as Metallo-β-lactamases. KPC-producing (class A β-lactamase) *P. aeruginosa* isolates have been occasionally reported in some countries since 2006 (Naas et al., 2013; Hu et al., 2015; Hagemann et al., 2018; Walkty et al., 2019). The blaKPC genes were frequently detected globally mainly among the species in the family *Enterobacteriaceae* (Feng et al., 2017). Some studies reported that blaKPC in CRPA might be transmitted from carbapenem-resistant *Enterobacteriaceae*. In China, KPC-2-producing *Pseudomonas aeruginosa* ST463 was first reported in 2015 and has rapidly spread in Zhejiang in recent years (Hu et al., 2015). However, clinical studies of BSIs by the emerging ST463 *P. aeruginosa* are still lacking.

In PA strains, the type III secretion system (T3SS) play a major role in their intrinsic virulence levels (Hauser, 2009). This secretion system injects potent cytotoxins into the cell and includes four effector proteins: exoU, a phospholipase; ExoS and ExoT, bifunctional proteins, and ExoY, an adenylyl cyclase (Engel and Balachandran, 2009). In recent years, the cytotoxic exoU virulence gene of *P. aeruginosa* has been found to be associated with severe disease and poor outcomes. Furthermore, it is an important independent marker of early death in patients with *P. aeruginosa* BSI (Halavaty et al., 2012; Sawa et al., 2014; Peña et al., 2015). Almost all strains encode for exoT and exoY (Feltman et al., 2001), but the coexistence of exoU and exoS genes has rarely been reported due to their frequent mutual exclusivity (Hauser, 2009; Bradbury et al., 2010; Oliver et al., 2015). Previous studies indicated that the exoU genotype was also related to individual resistance to several antipseudomonal agents, including fluoroquinolones, carbapenems, and cephalosporins (Engel and Balachandran, 2009; Peña et al., 2015). However, one report illustrated that the co-presence of exoU and exoS was associated with a greater capacity for multi-drug resistance (Horna et al., 2019).

Herein, we described the occurrence of BSIs caused by KPC-producing CRPA that belonged to ST463. We investigate the high mortality rates associated with it in a tertiary hospital in East China in 2019–2020. We characterized the genomic alterations in the ST463 CRPA population and ascertained associated changes in phenotype and pathogenicity traits.

**MATERIALS AND METHODS**

**Study Population**

We conducted a retrospective cohort study of CRPA BSI cases in a 2,500-bed public teaching hospital located in Zhejiang, China. The cases of CRPA BSIs were retrieved from the conventional microbiology laboratory database. The hospitalized patients with positive CRPA blood culture from January 2019 to December 2020 were selected. Five polymicrobial BSI cases were excluded from clinical analysis, but not from microbiological analysis. The study flowchart is shown in **Figure 1**. Only the first isolate was selected for each patient. This study was approved by the institutional review board of the First Affiliated Hospital of Zhejiang University in China (approval no. IIT20210120B). Informed consent was waived by the review board due to the nature of the study. A standardized case record form was used to
collect epidemiological and clinical data, as detailed in the Supplementary Materials.

**Microbiological Analysis**
Frozen CRPA isolates were cultured and reidentified by VITEK 2 system (bioMérieux, France). We confirmed minimum inhibitory concentrations (MICs) of twelve antipseudomonal agents. Imipenem, meropenem, piperacillin-tazobactam, ceftazidime, ceefepime, amikacin, gentamicin, ciprofloxacin, levofloxacin, aztreonam, and ceftazidime-avibactam were determined by the agar dilution method. The broth micro-dilution method was used to quantify antibacterial resistance against polymyxin. The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI, 2021) standards (Papp-Wallace et al., 2010). All 50 CRPA isolates were sequenced using an Illumina Hiseq 2500 instrument (Qiagen, Valencia, CA, USA), and annotation was provided using the RAST server. Multi-locus sequence typing (MLST) and antibiotic resistance genes were conducted by the CGE server (https://cge.cbs.dtu.dk). Virulence factors were searched using the Virulence Factor DataBase (http://www.mgc.ac.cn/VFs/) (Liu et al., 2019). To determine the clonal relatedness, we performed a genome-wide gene-by-gene comparison by applying the SeqSphere+ software. Single nucleotide polymorphisms (SNPs) analysis was further conducted on CRPA isolates of the same Sequence Type clone. One isolate (ZYPA01) was carried out with long-read sequencing using the PacBio RSII platform. Sequence identity among the blaKPC-2 flanking genes of the isolate and KPC-encoding plasmids from *P. aeruginosa* reported previously, *Escherichia coli* or *K. pneumoniae* isolates were assessed by Blast analysis. Descriptions of detailed bioinformatics analysis are available in the Supplementary material.

**Virulence Studies**
We did a serum resistance assay with all 50 CRPA strains. We randomly selected five ST463 CRPA (ZYPA08, ZYPA11, ZYPA23, ZYPA27, and ZYPA41) isolates as the representative for *G. mellonella* infection tests. The two assays were modified according to previously described protocols and are described in the Supplementary Methods. *P. aeruginosa* PAO1 was used as control.

**Statistical Analysis**
χ² or Fisher exact test was used for categorical variables and t-test or Mann-Whitney U test for continuous variables to compare different groups in our study. Univariate analysis and multivariate analysis were performed to determine the risk factors for 28-day mortality. Variables with a P value of ≤ 0.05 in the univariate analysis were used in the binary logistic regression analysis to identify independent predictors. Kaplan-Meier survival curves (log-rank test) were obtained with the survminer R package. Kaplan-Meier survival curves were obtained in different groups. Analyses were two-tailed and the P-value of < 0.05 was considered significant. SPSS for Windows (IBM®, version 16.0) was used for the analysis.

**RESULTS**

**Overall Cohort Clinical Data**
In this two-year analysis, we extracted and analyzed clinical data from the database for 45 patients with CRPA BSIs except for five polymicrobial cases. The epidemiological characteristics, clinical features, treatments, and clinical outcomes of the patients are listed in Table 1. The median age of our cohort was 56 years and 37.8% were over 65 years. Most of the patients were male (71.1%). Majority of the patients had hematologic conditions (19, 42.2%). More than half (55.7%) of the patients had a prior hospitalization, with a median length of stay of 19 days, and 35.6% had been admitted to the intensive care unit. Most patients had invasive procedures prior to CRPA BSI: 66.7% of the patients underwent central venous catheterization, followed by...
| Characteristic | Total (n = 45) | ST463 (n = 24) | Non-ST463 (n = 21) | P value |
|---------------|---------------|----------------|-------------------|---------|
| **Demographic** |               |                |                   |         |
| Sex (male)    | 32 (71.11)    | 18 (75.00)     | 14 (66.67)        | 0.54    |
| Age, years, median (IQR) | 56 (32.00-71.00) | 46.5 (25.25-66.00) | 65 (33.50-76.50) | 0.06    |
| Elderly (age>65y) | 17 (37.78)    | 7 (29.17)      | 10 (47.62)        | 0.20    |
| BMI, kg/m², mean (SD) | 21.71 (3.02)   | 21.55 (2.30)   | 21.97 (4.05)      | 0.74    |
| **Underlying medical conditions** |               |                |                   |         |
| Diabetes      | 6 (13.33)     | 2 (8.33)       | 4 (19.05)         | 0.54    |
| Lung disease  | 3 (6.67)      | 2 (8.33)       | 1 (4.76)          | 1.00    |
| Kidney disease| 5 (11.11)     | 2 (8.33)       | 3 (14.29)         | 0.87    |
| Hepatic disease| 8 (17.78)     | 4 (16.67)      | 4 (19.05)         | 1.00    |
| Benign biliary diseases | 2 (4.44) | 0 (0) | 2 (9.52) | 0.21 |
| Cardiovascular diseases | 15 (33.33) | 6 (25.00) | 9 (42.86) | 0.20 |
| Hematological disease | 19 (42.22) | 12 (50.00) | 7 (33.33) | 0.26 |
| Solid malignant tumor | 3 (6.67) | 1 (4.17) | 2 (9.52) | 0.60 |
| Solid-organ transplant | 6 (13.33) | 4 (16.67) | 2 (9.52) | 0.79 |
| **Hospital stay before BSI, median (IQR)** | 19 (9.50-30.50) | 20 (9.25-36.50) | 18 (10.00-28.50) | 0.36 |
| Nosocomial     | 38 (84.44)    | 22 (91.67)     | 16 (76.19)        | 0.31    |
| Trauma         | 3 (6.67)      | 2 (8.33)       | 1 (4.76)          | 1.00    |
| Surgery        | 22 (48.89)    | 12 (50.00)     | 10 (47.62)        | 0.87    |
| Pitt bacteremia score, median (IQR) | 3 (1.00-7.00) | 3.5 (1.00-9.25) | 2 (0.50-6.50) | 0.31 |
| Prior hospitalization (2 weeks) | 25 (55.56) | 13 (61.90) | 12 (50.00) | 0.42 |
| ICU (prior to bacteremia onset) | 16 (35.56) | 9 (37.50) | 7 (33.33) | 0.77 |
| CRPA BSI prior to hemodialysis | 11 (24.44) | 7 (29.17) | 4 (19.05) | 0.43 |
| **Prior invasive procedure and/or devices** |               |                |                   |         |
| Mechanical ventilation | 21 (47.73) | 12 (50.00) | 9 (45.00) | 0.74 |
| Urinary catheterization | 12 (27.91) | 7 (29.17) | 5 (26.32) | 0.84 |
| Central venous catheterization | 30 (66.67) | 16 (66.67) | 14 (66.67) | 1.00 |
| Percutaneous catheterization | 19 (42.22) | 13 (54.17) | 6 (28.57) | 0.08 |
| **Laboratory examination** |               |                |                   |         |
| White blood cell, median (IQR) | 7.2 (3.33-15.30) | 2.9 (0.23-11.85) | 12.5 (0.70-15.60) | 0.16 |
| Neutrophilic granulocyte, median (IQR)c | 5.6 (0.06-13.30) | 1.6 (<0.01-10.40) | 10.9 (0.20-14.10) | 0.21 |
| Red blood cell, median (IQR)d | 69 (62.50-105.50) | 67.5 (61.25-86) | 71 (63-117) | 0.23 |
| Hemoglobin, median (IQR)d | 50 (11.00-247.50) | 20 (9-168) | 118 (25-252) | 0.04 |
| Procalcitonin, median (IQR)c | 2.56 (0.42-15.05) | 2.68 (0.57-15.57) | 1.86 (0.21-17.67) | 0.51 |
| Albumin, median (IQR)d | 27.90 (24.30-29.93) | 27.10 (20.80-28.40) | 29.30 (25.40-31.90) | 0.03 |
| Agranulocytosis | 18 (40.00) | 11 (45.83) | 7 (33.33) | 0.39 |
| **Source of bacteremia** |               |                |                   |         |
| Lung           | 13 (28.89)    | 5 (20.83)      | 8 (38.10)         | 0.20    |
| Intra-abdominal infection | 2 (4.44) | 1 (4.17) | 1 (4.76) | 1.00 |
| Skin and soft-tissue infection | 3 (6.67) | 2 (8.33) | 1 (4.76) | 1.00 |
| Surgical sites | 1 (2.22)      | 1 (4.17)       | 0 (0.00)          | 1.00    |
| Catheter related| 4 (8.89)      | 1 (4.17)       | 3 (12.50)         | 0.70    |
| Urinary tract infection | 4 (8.89) | 3 (12.50) | 1 (4.76) | 0.70 |
| Unknown        | 19 (42.22)    | 10 (41.67)     | 9 (42.86)         | 0.94    |
| **Treatment**  |               |                |                   |         |
| Hormonal therapy | 29 (64.44) | 17 (70.83) | 12 (57.14) | 0.34 |
| Other immunotherapy | 20 (44.44) | 12 (50.00) | 8 (38.10) | 0.42 |
| **Antibiotic After BSI** |               |                |                   |         |
| Carbapenems + aminoglycosides | 15 (33.33) | 5 (20.83) | 10 (47.62) | 0.06 |
| Carbapenems + polymyxin B | 14 (31.11) | 4 (16.67) | 10 (47.62) | 0.03 |
| Ceftazidime-avibactam + aminoglycosides | 7 (15.56) | 1 (4.17) | 6 (28.57) | 0.07 |
| Ceftazidime-avibactam + carbapenems | 1 (2.22) | 0 (0.00) | 1 (4.76) | 0.47 |
| Ceftazidime-avibactam + polymyxin B | 4 (8.89) | 3 (12.50) | 1 (4.76) | 0.70 |
| **Mortality**  |               |                |                   |         |
| All-cause death at 7 d postbacteremia | 20 (44.44) | 14 (58.33) | 6 (28.57) | 0.06 |
| All-cause death at 14 d postbacteremia | 22 (48.89) | 15 (62.50) | 7 (33.33) | 0.06 |
| All-cause death at 28 d postbacteremia | 23 (51.11) | 16 (66.67) | 7 (33.33) | 0.03 |

Data are presented as no. (%) unless otherwise indicated. Bolded numbers indicate that P < 0.05.

IQR, interquartile range; BMI, body mass index; SD, standard deviation; AI, intra-abdominal infection; ICU, intensive care unit; BSI, bloodstream infection.
a. Evaluated 48 hours before or 24 hours after the first positive blood culture, whichever is the highest.
b. CRPA detected in the first blood culture.
c. The highest value before and after CRPA48 was detected in blood culture.
d. Lowest value at onset.
e. Including biliary tract and enteric canal.
mechanical ventilation (47.7%) and percutaneous catheterization (42.2%). Bacteremia was predominantly from respiratory tract infections (28.9%), followed by catheter-related and urinary tract infections (both 8.9%). Inflammatory indicators were elevated when bacteremia occurred. The median white blood cell (WBC) was 7.3*10^9/L, C-reactive protein (CRP) was 105.5 g/mL (increased), and procalcitonin (PCT) was 2.6 pg/mL (increased). Carbapenems combined with aminoglycosides were the most common antibiotic treatment (n = 15, 33.3%), followed by carbapenems combined with polymyxin B (n = 14, 31.1%). All-cause mortality rate at 7, 14 and 28 days was 44.4%, 48.9% and 51.1%, respectively. The clinical description of the 24 ST463 CRPA BSI cases is shown in Supplementary Table S1.

Clinical Analysis According to Sequence Type

The 50 CRPA strains isolated from patients belonged to 24 different STs. As shown in Figure 2A (MLST plot), ST463 was the predominant type (48.0%, 24/50), and the other 26 strains showed a high degree of ST diversity. The rate of the \( \text{bla}_{KPC} \) gene in ST463 CRPA was significantly higher than in non-ST463 CRPA (23/24, 95.8% vs 2/26, 6.7%; \( P < 0.001 \), Figure 2B).

After the exclusion of five polymicrobial BSIs cases, patients were divided into two groups, ST463 CRPA-infected (n=24) and non-ST463 CRPA-infected (n=21), to determine whether there was specificity in the clinical features of ST463-infected patients. Notably, all-cause mortality at days 7, 14, and 28 was higher in ST463-infected than in non-ST463-infected patients (58.3% vs 28.6%, 62.5% vs 33.3%, and 66.7% vs 33.3%, respectively) (Table 1). The 28-day survival curves based on different STs also showed a significant difference (\( P = 0.03 \)) as detailed in Figure 2C. Furthermore, the ST463-infected group had a higher median Pitt bacteremia score of 3.5 compared with the non-ST463-infected group with a score of 2 (\( P = 0.3 \)); this score is a predictor of early mortality risk in patients with BSI. There were no significant differences found in the clinical variables such as age, gender, underlying disease, or treatment received between the two groups; however, the amount of platelets was lower in the ST463-infected group (20 vs 118 *10^9/L, \( P=0.04 \)) (Table 2).

Mortality Predictor Analysis

Factors that may affect 28-day mortality in this CRPA BSI cohort were described in Table 2. Multivariate analysis confirmed the following as independent factors: \( \text{bla}_{KPC} \) carriage (odds ratio [OR], 4.9; 95% confidence interval [CI], 1.0-23.7; \( P = 0.05 \)), Pitt bacteremia score (odds ratio [OR], 1.3; 95% confidence interval [CI], 1.0-1.6; \( P = 0.02 \)), and underlying hematological disease (odds ratio [OR], 8.5; 95% confidence interval [CI], 1.6-46.4; \( P = 0.01 \)).

Isolates’ Genetic Relatedness, Antimicrobial Susceptibility Testing, Antibiotic Resistance Genes, and Virulence Factors

MLST and serotype analysis revealed that the 50 clinical strains belonged to 24 MLST types and eight serotypes, and \( P. \) aeruginosa ST463 strains were associated with serotype O4.

![FIGURE 2](image-url)
The connections between serotypes and STs in other isolates are shown in Figure 3A. The same figure also depicts the antibiotic resistance genes identified in the CRPA genome. In our study, bla<sub>KPC</sub> was found in the genomes of 23/24 ST463 isolates, including 22 bla<sub>KPC-2</sub> and 1 bla<sub>KPC-33</sub>; on the other hand, it was found only in one non-ST463 isolate (95.8% vs 3.8%, \( P < 0.001 \)). The prevalence of the fluoroquinolone-resistance gene (crpP) was also significantly higher in the ST463 group than in the non-ST463 group, and most ST463 isolates had two copies of the crpP gene (Figure 2A). All ST463 strains carried bla<sub>ONX-486</sub> \( \beta \)-lactamase gene, while the non-ST463 strains were genotyped with dispersed oxacillinases. Other resistance genes did not show differences between the two groups. We also found some significant differences in T3SS virulence factors between ST463 and non-ST463 CRPA strains (Figure 2A). All ST463 isolates coharbored exoU and exoS genes. However only 4/26 (15.4%) of the non-ST463 CRPA isolates carried exoU gene, and the other 22/26 non-ST463 strains carried the exoS gene without exoU.

Antimicrobial susceptibilities were summarized in Table 3 and Figure 2A. ST463 CRPA isolates were highly resistant to imipenem and meropenem (MIC<sub>50</sub> 256 mg/L; 100% resistance). The MIC<sub>50</sub> of carbapenems for ST463 CRPA isolates were 8- to 16-fold higher than for non-ST463 CRPA isolates: imipenem (MIC<sub>50</sub> 32 mg/L; 100% resistance) and meropenem (MIC<sub>50</sub> 16 mg/L; 84.6% resistance). Also, ST463 isolates show statistically significant difference in higher resistant rates to piperacillin-tazobactam (91.7% vs 26.9% resistance), ciprofloxacin (100% vs 38.5% resistance), levofloxacin (100% vs 42.3% resistance), ceftazidime (95.8% vs 19.2% resistance), cefepime (95.8% vs 30.8% resistance), and aztreonam (100% vs 42.3% resistance), to those of non-ST463 CRPA isolates (\( P < 0.001 \)). Notably, all of the CRPA were less frequently resistant to ceftazidime-avibactam, amikacin and polymyxin.

Based on sequence analysis of the whole genome, the phylogenetic tree showed that 22 of the 24 ST463 CRPA isolates belonged to the same cgMLST cluster 1, except for isolates of ZYPA36 and ZYPA31 (Figure 3B). For further core-genome SNPs, the average pairwise distance between two isolates is 99.95 SNPs and ranges from 1 to 2273 SNPs. Within the ST463 group, one strain genome (ZYPA01) was fully assembled for further analysis. pZYPA01, a unique plasmid, carried the sole resistance gene bla<sub>KPC-2</sub>, and no virulence genes were found (Supplementary Figure S1A). It could not be assigned to any known incompatibility group. Blast analysis of the pZYPA01 sequence revealed that it was highly similar to pPA1011 (GenBank accession number MH734334.1), a plasmid carrying carbapenem-resistant gene bla<sub>KPC-2</sub> from an ST463 P. aeruginosa isolate in Hangzhou, China, with 99.1% identities and 99.0% query coverage (Supplementary Figure S1A). The plasmid pZYPA01 sequence was also highly similar to the plasmid sequence harboring the bla<sub>KPC-33</sub> (pZP54), with 99.1% identities and 99.0% query coverage. The core bla<sub>KPC-2</sub> platform Tn3-tnpA-ISKpn27-bla<sub>KPC-2</sub>-ISKpn6 had also been found in pPA1011 from P. aeruginosa, pKP048 from K. pneumoniae and pHS102707 from Escherichia coli (Supplementary Figure S1B). Unlike the mobile genetic element described in pPA1011, pKP048, and pHS102707 (Tn3-ISKpn8-bla<sub>KPC-2</sub>-ISKpn6), bla<sub>KPC-2</sub> in pZYPA01 was
FIGURE 3  | (A) Genetic relatedness, antibiotic resistance genes, virulence factor determinants, and antimicrobial susceptibility testing results of 50 CRPA BSI strains. These features are shown separately on the four blocks of the picture. The gray value indicates the copy number of the antibiotic resistance gene and virulence factors blaKPC-2 and ST463 are highly associated (22 out of 24; 91.7%). R, resistant; I, Intermediate; S, Sensitive. (B) Minimum spanning trees of 24 ST463 CRPA BSI strains from cgMLST analysis. Distance based on 4823 targets genes with pairwise ignore missing values. CgMLST profiles are represented by circles. The shaded parts represent the same cluster with a distance threshold of 10. The size of the circle is proportional to the number of isolates sharing the same cgMLST profile, with the biggest one including five isolates; (C) Neutrophil-killing resistance; at the maximum growth rate of KPC and non-KPC group; (D) Virulence potential in a G mellonella infection model. Five isolates of ST463 and five isolates of other STs representing various genetic background were randomly selected for the infection assay at 10⁵ CFU. P values were calculated by log-rank (Mantel-Cox) test. Each line represents a single isolate. Isolate PA-O1 was used as the control. Abbreviation: CFU, colony-forming units.

TABLE 3 | Antimicrobial susceptibilities of 24 ST463 and 26 Non-ST463 Carbapenem-Resistant P. aeruginosa isolates.

| Antibiotic(s) | ST463 (n = 24) | Non-ST463 (n = 26) | P value (R%) |
|---------------|---------------|-------------------|--------------|
|               | Resistance rate (%) | MIC50 (µg/mL) | MIC90 (µg/mL) | MIC range (µg/mL) | MIC50 (µg/mL) | MIC90 (µg/mL) | MIC range (µg/mL) |               |
| Imipenem      | 100           | 256              | 256           | 32 - 512          | 100           | 32              | 256           | 8 - 256         | 1             |
| Meropenem     | 100           | 256              | 256           | 128 - 512         | 84.6          | 16              | 256           | 0.125 - 256     | 0.138         |
| Piperacillin-tazobactam | 91.7 | >256             | >256          | 16 - 512          | 26.9          | 16              | 256           | 4 - 512         | <0.001 |
| Ceftazidime   | 95.8          | 256              | 256           | 8 - 256           | 19.2          | 8               | 256           | 2 - 128         | <0.001 |
| Cefepime      | 95.8          | 128              | 256           | 16 - 512          | 30.8          | 8               | 128           | 2 - 256         | <0.001 |
| Amikacin      | 12.5          | 8                | 256           | 2 - 256           | 0             | 8               | 16            | 1 - 32          | 0.206         |
| Gentamycin    | 20.8          | 6                | 256           | 2 - 256           | 30.8          | 8               | 16            | 1 - 32          | 0.424         |
| Ceftobiprole  | 100           | 32               | 64            | 16 - 64           | 38.5          | 1               | 32            | 0.25 - 32       | <0.001 |
| Levofloxacin  | 100           | 128              | 128           | 32 - 128          | 42.3          | 4               | 64            | 1 - 128         | <0.001 |
| Aztreonam     | 100           | 256              | 256           | 32 - 512          | 42.3          | 16              | 256           | 1 - 256         | <0.001 |
| Ceftazidime-avibactam | 8.3 | 8                | 8             | 2 - 256           | 3.8           | 2               | 8             | 1 - 32          | 0.943         |
| Polymyxin     | 0             | 1                | 1             | 1 - 2             | 3.8           | 1               | 2             | 1 - 4           | 1             |

Bolded p-values indicate P ≤ 0.05.
carried on a 7-kb composite transposon-like element flanked by two IS26 elements (IS26–Tn3–tnpA–ISKpn27–bla<sub>KPC-2</sub>–ISKpn6–IS26), hence making it potentially transferable.

**Virulence Assessment With Serum Killing and G. mellonella Infection Assays**

In our study, all strains were tested in 20% human serum to investigate their capacity to resist the serum bactericidal activity. Subgroup analysis showed that the maximum growth rate of KPC-positive isolates was significantly lower compared to -negative isolates (Figure 3C, P = 0.04). Although there was no statistical difference, the maximum growth rate was also lower in the ST463-CRPA group than in the non-ST463-CRPA (P = 0.24).

We randomly selected five representative ST463 isolates and five non-ST463 isolates to test the virulence properties of these strains. Continuous monitoring for 96 hours, even at the lowest concentration (10<sup>3</sup> cfu), the mortality rate of the ST463-infected larvae group was higher than in the non-ST463-infected. Of all isolates tested, the ST463 isolates PAZY06 were the most virulent strains in all inocula tested (Figure 3D).

**DISCUSSION**

A recent increase in the detection rate of CRPA has been observed in Zhejiang Province, China, from 22% in 2015 to 32% in 2020; it is also significantly higher than in other provinces (Hu et al., 2019; Hu et al., 2021a; Hu et al., 2021b). In a recent report from a hospital in Zhejiang, ST463 CRPA emerged and has become the predominant CRPA clone among the population (Hu et al., 2021a). To date, there is still a lack of clinical studies on bloodstream infections of the new-onset KPC-producing CRPA belonging to ST463. Despite the retrospective and single-center nature of this study, it provides a uniquely detailed clinical and microbiological description of a KPC-producing ST463 CRPA BSI cohort from a Chinese hospital.

Conventionally, ST175, ST111, ST235, and ST395 are high-risk PA clones in clinics worldwide (Oliver et al., 2015). However, in our recent two-year study on the CRPA BSI cohort (2019-2020), none of the above international “high-risk” STs were isolated and ST463 has become the dominant CRPA clone in the population causing BSI (48.0%). Baseline characteristics showed no statistical differences in clinical variables across STs. However, 28-day mortality was significantly higher in ST463 cases than in non-ST463 cases. Of the 24 ST463 CRPA BSI cases in the cohort, 16 patients succumbed within 28 days. These BSIs were mainly from the respiratory tract. Indeed, several studies demonstrated that the initial site of infection affects prognosis, with surgery and pneumonia being associated with a particularly poor prognosis for *P. aeruginosa* bloodstream infections (Chatzinikolaou et al., 2000; Feng et al., 2017). In our study, *bla<sub>KPC</sub>* carriage, Pitt bacteremia score, and underlying hematological disease were three independent risk factors contributing to 28-day fatal outcomes. The survival curves also showed lower survival in KPC-positive ST463 CRPA-infected patients compared to those who are KPC-negative non-ST463 CRPA-infected (Figures 2D, E). The detection rate of *bla<sub>KPC</sub>* was also significantly higher in the ST463 group than in the non-ST463 group (95.8% vs 3.8%, P < 0.001). This suggests that the dominant clone of CRPA BSIs, ST463, has a high correlation with the *bla<sub>KPC</sub>* gene and the poor prognosis of BSIs.

Although metallo-β-lactamas (MBLs) were found to be the most frequent carbapenemases in CRPA, no MBL genes were found in either ST463 or non-ST463 isolates in this study. Moreover, the β-lactamase KPC was produced in almost all ST463 CRPA isolates. This is quite different from the results of our multicenter study conducted in China 10 years ago, when MBL genes including IMP and VIM were detected in 8.5% of CRPA isolates, while no KPC isolates were detected (Wang et al., 2010). Generally, KPC is detected from the *Enterobacteriaceae* family, including *K. pneumoniae* and *E. coli*; this leads to high levels of resistance to carbapenem and other β-lactam antibiotics. Therefore, we compared the surrounding sequences of *bla<sub>KPC</sub>*-containing plasmid sequences from different species including *P. aeruginosa* and *Enterobacteriaceae*. The results showed that each plasmid from various species presented core *bla<sub>KPC-2</sub>* was franked by mobile genetic element ISKpn27 and ISKpn6 (Supplementary Figure S1B). This supports the hypothesis that *bla<sub>KPC</sub>* in *P. aeruginosa* might be acquired from *Enterobacteriaceae* (Queenan and Bush, 2007; Naas et al., 2013; Hu et al., 2021a).

All 24 ST463 (O4) CRPA isolates carried the *exoU* and *exoS* virulence genes, but not *PldA*, which was somewhat different from the reported strains from 2009 to 2018 (Hu et al., 2021a). Previously *exoU* and *exoS* were always reported to be mutually exclusive (Vareechon et al., 2017); while the coexistence of *exoU* and *exoS* may enhance the resistance of *P. aeruginosa* (Horna et al., 2019). In this study, all ST463 strains carried both *exoS* and *exoU* genes, while non-ST463 strains carried only one of them (15.4% *exoU* and 84.6% *exoS*), consistent with the results of higher resistance of ST463. On the other hand, the group of KPC-ST463-infected larvae had a higher mortality rate than other STs group. In 20% human serum, the maximum growth rate of KPC-negative CRPA group. Thus, *in vitro* virulence phenotyping experiments showed that KPC was another independent risk factor associated with high lethality. We could further indicate that *exoU* and *exoS* virulence genes coexisting with *bla<sub>KPC</sub>* resistance gene in ST463 CRPA may be an important intrinsic cause of poor prognosis of clinical PA BSIs. This may lead to a new threat at the clinic.

In 2021, the Infectious Diseases Society of America (IDSA) recommended cefozolane-tazobactam, ceftazidine-avibactam, and imipenem-cilastatin-relebactam as monotherapy first-line treatment options for difficult-to-treat *P. aeruginosa* (DTR-PA) infections (Tamma et al., 2021). In our study, the results of antimicrobial susceptibility testing showed that ST463 CRPA isolates were fairly susceptible to amikacin (87.5%) and ceftazidine-avibactam (91.7%). It is suggested that ceftazidine-avibactam or ceftazidine-avibactam combined with amikacin may be a good option for the treatment of infections caused by
KPC-producing ST463 CRPA. For adult patients with severe infections, assuming normal renal and liver function, the recommended intravenous dose of ceftazidime-avibactam is 2.5 g every 8 hours, infused over 3 hours. However, more fluoroquinolone-resistant ST463 strains were detected compared to non-ST463 strains, as the prevalence of the crpP gene were also significantly higher in ST463 strains (mostly two copies of crpP). While no plasmid-mediated coding genes (e.g. qnr, aac (6')-Ib-cr) were found, no other mechanisms of fluoroquinolone resistance such as chromosomal mutation in the DNA gyrase and topoisomerase II/IV-encoding genes (parC, parE, gyrA, and gyrB) were further investigated. Another noteworthy issue is that most MICs of polymyxin were 1 μg/mL and the effective therapeutic dose should be large and in combination (Nang et al., 2021). For patients on polymyxin B, the recommended loading dose is 2.0-2.5 mg/kg based on total body weight (TBW) (equivalent to 20,000–25,000 IU/kg) over 1 hour. And the daily maintenance dose is 1.25-1.5 mg/kg (equivalent to 12,500–15,000 IU/kg TBW) every 12 hours infused over 1 hour (Tsuji et al., 2019). High dose exposure to polymyxin has the potential to cause nephrotoxicity, hence limiting the therapeutic value (Lakota et al., 2018).

In conclusion, we described a BSI cohort by a novel high-risk KPC-PA ST463 clone that has been rapidly emerging and disseminating in East China in recent years. In the current study, we found a higher mortality rate in the ST463 CRPA BSI cohort than in the non-ST463 CRPA BSI. ST463 was the predominant epidemic type of KPC-producing CRPA. The independent risk factors for a 28-day outcome of CRPA BSI were blaKPC-carrying *P. aeruginosa* and hematological disease. Prompt and effective treatment of ST463 CRPA infection might reduce mortality, especially in patients with underlying hematological disease. These results also suggest that epidemiological surveillance is still needed to monitor the dynamic changes of high-risk clones, such as ST463 CRPA.

**REFERENCES**

Bradbury, R. S., Roddam, L. F., Merritt, A., Reid, D. W., and Champion, A. C. (2010). Virulence Gene Distribution in Clinical, Nosocomial and Environmental Isolates of Pseudomonas Aeruginosa. *J. Med. Microbiol.* 59 (Pt 8), 881–890. doi: 10.1099/jmm.0.018283-0

Chatzinikolaou, I., Abi-Said, D., Bodey, G. P., Rolston, K. V., Tarrand, J. J., and Samonis, G. (2000). Recent Experience With Pseudomonas Aeruginosa Bacteremia in Patients With Cancer: Retrospective Analysis of 245 Episodes. *Arch. Intern. Med.* 160 (4), 501–509. doi: 10.1001/archinte.160.4.501

Doi, Y. (2019). Treatment Options for Carbapenem-Resistant Gram-Negative Bacterial Infections. *Clin. Infect. Dis.* 69 (Suppl 7), S56–S75. doi: 10.1093/cid/ciz830

Engel, J., and Balachandran, P. (2009). Role of Pseudomonas Aeruginosa Type III Effectors in Disease. *Curr. Opin. Microbiol.* 12 (4), 61–66. doi: 10.1016/j.mib.2008.12.007

Feltman, H., Schulte, G., Khan, S., Jain, M., Peterson, L., and Hauser, A. R. (2001). Prevalence of Type III Secretion Genes in Clinical and Environmental Isolates of Pseudomonas Aeruginosa. *Microbiol. (Reading)* 147 (Pt 10), 2659–2669. doi: 10.1099/00221287-147-10-2659

Feng, J., Yin, Z., Zhao, Q., Zhao, Y., Zhang, D., Jiang, X., et al. (2017). Genomic Characterization of Novel IncII-Type Multidrug Resistant Plasmids P0716-KPC and P12181-KPC From Klebsiella Pneumoniae. *Sci. Rep.* 7 (1), 5830. doi: 10.1038/s41598-017-06283-2

Hagemann, J. B., Pfennigwerth, N., Gatermann, S. G., von Baum, H., and Essig, A. (2018). KPC-2 Carbapenemase-Producing Pseudomonas Aeruginosa Reaching Germany. *J. Antimicrob. Chemother.* 73 (7), 1812–1814. doi: 10.1093/jac/dky105

Halavaty, A. S., Borek, D., Tyson, G. H., Veesenmeyer, J. L., Shuvalova, L., Minasov, G., et al. (2012). Structure of the Type III Secretion Effector Protein Exou in Complex With its Chaperone Spcu. *PloS One* 7 (11), e49388. doi: 10.1371/journal.pone.0049388

Hauser, A. R. (2009). The Type III Secretion System of Pseudomonas Aeruginosa: Infection by Injection. *Nat. Rev. Microbiol.* 7 (9), 654–665. doi: 10.1038/nrmicro2199

Horn, G. A.-O., Amaro, C., Palacios, A., Guerra, HA-OX, and Ruiz, J. A.-O. (2019). High Frequency of the Exou+/Exos+ Genotype Associated With Multidrug-Resistant “High-Risk Clones” of Pseudomonas Aeruginosa Clinical Isolates From Peruvian Hospitals. *Sci. Rep.* 9 (1), 10874. doi: 10.1038/s41598-019-47303-4

Hu, Y. Y., Cao, J. M., Yang, Q., Chen, S., Lv, H. Y., Zhou, H. W., et al. (2019). Risk Factors for Carbapenem-Resistant Pseudomonas Aeruginosa, Zhejiang Province, China. *Emerg. Infect. Dis.* 25 (10), 1861–1867. doi: 10.3201/eid2510.181699

Hu, Y.-y., Gu, D.-x., Cai, J.-c., Zhou, H.-w., and Zhang, R. (2015). Emergence of KPC-2-Producing Pseudomonas Aeruginosa Sequence Type 463 Isolates in Hangzhou, China. *Antimicrob. Agents Chemother.* 59 (5), 2914–2917. doi: 10.1128/AAC.04903-14

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**AUTHOR CONTRIBUTIONS**

JW, YZ, MY, QYu, and HF collected clinical data. WS, HH, YC, YZ, HC, and PZ performed laboratory work. YJ, HH, and PZ performed whole-genome sequencing and bioinformatics analysis. TQ, HH, SZ, HF, and PZ analyzed clinical and microbiological data. TQ, HH, and QYa prepared the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by research grants from the National Natural Science Foundation of China (No. NSFC81871689).

**ACKNOWLEDGMENTS**

The authors thank all patients who participated in this study and all members of our institution for their help.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.756782/full#supplementary-material
Hu, Y., Liu, C., Wang, Q., Zeng, Y., Sun, Q., Shu, L., et al. (2021a). Emergence and Expansion of a Carbenapenem-Resistant Pseudomonas Aeruginosa Clone Are Associated With Plasmid-Borne Bla (KPC-2) and Virulence-Related Genes. mSystems 6 (3), e00154–21. doi: 10.1128/mSystems.00154–21

Hu, F. P., Guo, Y., Zhu, D. M., Wang, F., Jiang, X. F., Xu, Y. C., et al. (2021b). CHINET 2020 Surveillance of Bacterial Resistance in China. Chin. J. Infect. Chemother. 21 (4), 377–387. doi: 10.16718/j.1009-7708.2021.04.001

Lakota, E. A., Landersdorfer, C. B., Nation, R. L., Li, J., Kaye, K. S., Rao, G. G., et al. (2018). Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Antimicrob. Agents Chemother. 62 (7), e00483–18. doi: 10.1128/AAC.00483–18

Li, H., Luo, Y. F., Williams, B. J., Blackwell, T. S., and Xie, C. M. (2012). Structure of FepA, a Member of the Outer Membrane Porin Family. J. Med. Microbiol. 61 (2), 63–68. doi: 10.1099/jmm.0.2011.00011

Liu, B., Zheng, D., Jin, Q., Chen, L., and Yang, J. (2019). VFDB 2019: A Comparative Pathogenomic Platform With an Interactive Web Interface. Nucleic Acids Res. 47 (D1), D687–D692. doi: 10.1093/nar/gky1080

Naas, T., Bonnin, R. A., Cuzon, G., Villegas, M.-V., and Nordmann, P. (2013). Complete Sequence of Two KPC-Producing Plasmids From Pseudomonas Aeruginosa. J Antimicrob. Chemother. 68 (8), 1757–1762. doi: 10.1093/jac/dkt094

Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. T., and Li, J. (2019). Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol. Rev. 73 (2), 679–728. doi: 10.1124/pharmrev.120.00020

Oliver, A., Mulet, X., Lopez-Causape, C., and Juan, C. (2015). The Increasing Threat of Pseudomonas Aeruginosa High-Risk Clones. Drug Resist. Update 21–22, 41–59. doi: 10.1016/j.jchom.2015.08.002

Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J., and Cheng, Z. (2019). Antibiotic Resistance in Pseudomonas Aeruginosa and Acinetobacter baumannii: Mechanisms and Alternative Therapeutic Strategies. Biotechnol. Adv. 37 (1), 177–192. doi: 10.1016/j.biotechadv.2018.11.013

Papp-Wallace, K. M., Bethel, C. R., Distler, A. M., Kasuboski, C., Taracila, M., and Bonomo, R. A. (2010). Inhibitor Resistance in the KPC-2 Beta-Lactamase, A Preeminent Property of This Class a Beta-Lactamase. Antimicrob. Agents Chemother. 54 (2), 890–897. doi: 10.1128/AAC.00693-09

Peña, C., Cabot, G., Gómez-Zorrilla, S., Zamorano, L., Ocampo-Sosa, A., Murillas, J., et al. (2015). Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas Aeruginosa Bloodstream Infections. Clin. Infect. Dis. 60 (4), 539–548. doi: 10.1093/cid/ciu866

Potron, A., Poirel, L., and Nordmann, P. (2015). Emerging Broad-Spectrum Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and Epidemiology. Int. J. Antimicrob. Agents 45 (6), 568–585. doi: 10.1016/j.ijantimicag.2015.03.001

Queenan, A. M., and Bush, K. (2007). Carbapenemases: The Versatile Beta-Lactamases. Clin. Microbiol. Rev. 20 (3), 440–458. table of contents. doi: 10.1128/CMR.00001-07

Sawa, T., Shimizu, M., Moriyama, K., and Wiener-Kronish, J. P. (2014). Association Between Pseudomonas aeruginosa Type III Secretion, Antibiotic Resistance, and Clinical Outcome: A Review. Crit. Care 18, 668. doi: 10.1186/s13054-014-0668-9

Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., and Clancy, C. J. (2021). Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Beta-Lactamase Producing Enterobacteriales (ESBL-E), Carbenapenem-Resistant Enterobacteriales (CRE), and Pseudomonas aeruginosa With Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 72 (7), 1109–1116. doi: 10.1093/cid/ciaa295

Thaden, J. T., Park, L. P., Maskarinec, S. A., Ruffin, F., Fowler, V. G. Jr., and van Duin, D. (2017). Results From a 13-Year Prospective Cohort Study Show Increased Mortality Associated With Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob. Agents Chemother. 61 (6), e02671–16. doi: 10.1128/AAC.02671-16

Tsuij, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., et al. (2019). International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39 (1), 10–39. doi: 10.1002/phar.2209

Varechon, C., Zmina, S. E., Karmakar, M., Pearlman, E., and Rietsch, A. (2017). Pseudomonas aeruginosa Effector Exos Inhibit ROS Production in Human Neutrophils. Cell Host Microbe 21 (5), 611–618.e5. doi: 10.1016/j.chom.2017.04.001

Waltky, A., Alexander, D. C., Karlowsky, I. A., Nichol, K., and Embil, J. (2019). Report of a KPC-Producing Pseudomonas aeruginosa Isolate in Canada. J. Antimicrob. Chemother. 74 (6), 1748–1749. doi: 10.1093/jac/dkz064

Wang, I., Zhou, J. Y., Qu, T. T., Shen, P., Wei, Z. Q., Yu, Y. S., et al. (2010). Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates From Chinese Hospitals. Int. J. Antimicrob. Agents 35 (5), 486–491. doi: 10.1016/j.ijantimicag.2009.12.014

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hu, Zhang, Zhang, Wang, Yuan, Shi, Zhang, Peng, Chen, Yu, Chen, Jiang, Yang and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is